Clinical and Experimental Allergy最新文献

{"title":"Real-World Evaluation of Associations Between Regular Intake and Food Challenge Outcome in Children.","authors":"Sayaka Hamaguchi, Limin Yang, Chisato Jimbo, Tomoki Yaguchi, Marei Omori, Kouhei Hagino, Daisuke Harama, Daichi Suzuki, Kotaro Umezawa, Fumi Ishikawa, Seiko Hirai, Kenji Toyokuni, Tatsuki Fukuie, Yukihiro Ohya, Yoshiyuki Yamamada, Kiwako Yamamoto-Hanada","doi":"10.1111/cea.70097","DOIUrl":"https://doi.org/10.1111/cea.70097","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct Cytokine Profiles in Chronic Spontaneous Urticaria Refractory to H1-Antihistamines Compared to Healthy Controls.","authors":"Young-Min Ye, Hyun-Young Lee, Da-Hye Moon, Kun-Woo Park, Se-Min Park","doi":"10.1111/cea.70095","DOIUrl":"https://doi.org/10.1111/cea.70095","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of the Top 15 Drugs Associated With Anaphylaxis: A Pharmacovigilance Study.","authors":"Tae Hyeon Kim, Jaeyu Park, Hyesu Jo, Jeongseon Oh, Kyeongmin Lee, Jiyeon Oh, Hayeon Lee, Lee Smith, Guillermo F López Sánchez, Yerin Hwang, Dong Keon Yon","doi":"10.1111/cea.70092","DOIUrl":"https://doi.org/10.1111/cea.70092","url":null,"abstract":"<p><strong>Background: </strong>Drug-associated anaphylaxis is a common condition with significant risks if not promptly addressed. Yet, systematic research on the distribution of associated drugs and risk comparison across drug classes is limited. This study aims to identify frequently reported drugs and evaluate the strength of their signal detections with drug-associated anaphylaxis.</p><p><strong>Methods: </strong>This study employed a global pharmacovigilance database to identify reports of drug-associated anaphylaxis. Reports classified as anaphylaxis were analysed using the drug record number used in global pharmacovigilance database, leading to the identification of 15 frequently associated drugs. A disproportionality analysis was conducted to estimate signal detections between these selected drugs and anaphylaxis, utilising two metrics: the information component (IC) with a threshold of IC_0.25 and the reporting odds ratio (ROR) with 95% confidence intervals (CI). To account for the acute onset of anaphylaxis, a sensitivity analysis focused on reports with a time to onset of less than a day.</p><p><strong>Results: </strong>We identified 15 drugs frequently associated with anaphylaxis, with diclofenac recording the highest number of reports at 34,413. The drug indicating the strongest signal detection with anaphylaxis was cefuroxime (ROR, 40.89 [95% CI, 40.18-41.61]; IC, 5.14 [IC_0.25, 5.11]), followed by levofloxacin, ibuprofen, COVID-19 vaccine, ceftriaxone, lidocaine, omalizumab, cefuroxime, benzylpenicillin, clindamycin, amoxicillin/clavulanate, cefazolin, ciprofloxacin, metronidazole, and paclitaxel. Sensitivity analysis indicated that the signal detection between the COVID-19 vaccine and anaphylaxis was stronger than in the primary analysis (ROR, 2.49 [95% CI, 2.45-2.53]; IC, 1.23 [IC_0.25, 1.21]). While most drugs reported that the majority of drug-associated anaphylaxis reports occurred within 2.5 h, omalizumab was often associated with reactions occurring after 24 h.</p><p><strong>Conclusion: </strong>All drugs frequently reported in association with anaphylaxis indicated a significant signal detection, but the strength of these signal detections did not align with the number of reports. Time-to-onset analysis showed distinct patterns for certain drugs, suggesting different mechanisms of anaphylaxis. Due to the limitations of spontaneous reporting databases with disproportionality analysis, our findings do not permit for causal inference.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Efficacy and Safety of Dupilumab Retreatment in Adults With Relapsed Atopic Dermatitis: A Retrospective Study From China.","authors":"Anda Zhang, Xu Li, Hong Liu, Furen Zhang","doi":"10.1111/cea.70093","DOIUrl":"https://doi.org/10.1111/cea.70093","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Usefulness of Detecting IgE Content and Profile Specific to 14 Epitopes Defined in Cow's Milk Allergen.","authors":"Kiyoaki Ito, Ikuo Okafuji, Mitsuhiro Kawano, Yusei Ohshima, Yoshihiro Watanabe","doi":"10.1111/cea.70091","DOIUrl":"https://doi.org/10.1111/cea.70091","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectories of IgE, IgA and IgG Levels in Preschool-Aged Children: Insights From the Subcohort Study of the Japan Environment and Children's Study.","authors":"Yumiko Miyaji, Limin Yang, Daisuke Harama, Mayako Saito-Abe, Miori Sato, Kei Sakamoto, Minaho Nishizato, Natsuhiko Kumasaka, Hidetoshi Mezawa, Yukihiro Ohya, Kiwako Yamamoto-Hanada","doi":"10.1111/cea.70085","DOIUrl":"https://doi.org/10.1111/cea.70085","url":null,"abstract":"<p><strong>Background: </strong>There is a significant lack of longitudinal research on specific immunoglobulin E (IgE), IgA, and IgG sensitisation levels among preschool-aged children, despite their critical role in elucidating the mechanisms underlying allergic disorders. The current study analysed the trajectories of IgE, IgA, IgG1, and IgG4 levels across general populations and their correlation with allergic diseases in children aged 2-4 years.</p><p><strong>Methods: </strong>This longitudinal study included 4872 children aged 2 years and 4437 children aged 4 years who participated in the Subcohort Study of the Japan Environment and Children's Study. Allergic diseases were evaluated utilising the diagnostic criteria established by the International Study of Asthma and Allergies in Childhood and the UK Working Party. The serum specific IgE (sIgE), IgG1, IgG4, and IgA levels of participants aged 2-4 years were quantified.</p><p><strong>Results: </strong>The prevalence of atopic dermatitis, hen's egg allergy, cow's milk allergy, and current wheezing decreased between ages 2 and 4 years. The prevalence of allergic rhinitis and conjunctivitis exhibited an upward trend. The serum IgE levels to hen's egg and cow's milk antigens in healthy children were similar to those in children with allergic diseases, and it decreased between ages 2 and 4 years. Der p1 sIgE levels decreased in healthy children, whereas they increased in allergic children. The high sIgE/total IgE and sIgE/specific IgG4 levels to Derf1 and Derp1 at age 2 years were associated with current wheezing at age 4 years.</p><p><strong>Conclusions: </strong>This study provided foundational benchmark values for IgE, IgG1, IgG4, and IgA levels against different allergens in a general population of children aged < 5 years. The levels of each allergen exhibited distinct characteristics in the general population.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes.","authors":"Timothy C Chin-See-Chong, Jasper H Kappen, Elizabeth Palmer, Janice A Layhadi, Mohamed H Shamji, Johanna P M van der Valk","doi":"10.1111/cea.70084","DOIUrl":"https://doi.org/10.1111/cea.70084","url":null,"abstract":"<p><p>Asthma is a complex, heterogeneous disease characterised by clinical phenotypes demonstrating distinct and overlapping immunological mechanisms, classified into type-2 high and type-2 low asthma endotypes. Both allergic and eosinophilic non-allergic asthma are driven through an underlying type-2 high-endotype, which can be targeted using therapeutic approaches such as allergen-specific immunotherapy (AIT) for allergic asthma and biologics. AIT demonstrates efficacy for the treatment of allergic asthma. Approved biologics for asthma management include using various interleukin antagonists and anti-immunoglobulin E, with Tezepelumab offering promising treatments for both type-2 high and type-2 low asthma patients. Novel therapeutic candidates, such as Itepekimab and depemokimab, have demonstrated promising results in a Phase 2 clinical trial in moderate-to-severe asthma patients.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology, Diagnosis and Prevention of Allergic Rhinitis in High-Pollen Areas of Northern China.","authors":"T T Ma, C E Fan, X Tong, C Y An, H J Cai, L Y Ai, Y F Li, D Y Wang, X D Wang, G L Shang, Y D Hu, Y F Bai, Y L Chen, H T Wang, H Y Ning, L Zhang, J J Zhang, X Y Wang","doi":"10.1111/cea.70087","DOIUrl":"https://doi.org/10.1111/cea.70087","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction.","authors":"Renaud Louis, Marek Lommatzsch, David J Jackson, Andrew Menzies-Gow, Anat Shavit, David Cohen, Flavia C L Hoyte, Stephanie Korn","doi":"10.1111/cea.70083","DOIUrl":"https://doi.org/10.1111/cea.70083","url":null,"abstract":"<p><p>The introduction of biologics, such as benralizumab (an anti-IL-5 receptor α humanised monoclonal antibody), has made remission a feasible goal for patients with severe eosinophilic asthma (SEA). However, there are remaining research gaps and no clear consensus on the definition of remission. We consolidated post hoc remission data from clinical trials and real-world studies of benralizumab in patients with SEA to gather insights on: testing different definitions; predictors of remission; the effect of comorbidities on achieving remission; remission and background medication reduction; long-term remission patterns with benralizumab; and remission in a real-life setting. In the SIROCCO and CALIMA Phase 3 randomised studies, patients with remission had higher baseline median blood eosinophil counts, were more likely to have a FEV₁ of ≥ 65% predicted, had fewer exacerbations within 12 months and had lower mean ACQ-6 scores. Compared with the overall population, patients with a history of nasal polyps were also more likely to achieve remission with benralizumab. Analyses of the BORA and MELTEMI extension studies showed that in the longer term, once remission is achieved with benralizumab, patients are likely to remain in remission with continued treatment. In the open-label, single-arm ANDHI-In Practice and PONENTE studies, patients achieving remission had a shorter median time since asthma diagnosis, higher median age at asthma onset and lower median ACQ-6 scores. The SHAMAL study and the Phase 3b ANDHI-In Practice substudy demonstrate that remission is maintained with benralizumab even when patients reduce their background medication. Finally, the XALOC-1 real-world study highlights how patients with lower BMI are more likely to achieve remission with benralizumab. These findings demonstrate that achieving remission in patients with SEA is feasible with benralizumab and, in turn, inform future directions for research and treatment that includes a promising shift towards a new era of treat-to-target. This manuscript was supported by AstraZeneca, the manufacturer of benralizumab.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Food Challenges for Food Protein-Induced Enterocolitis Syndrome-A 10-Year Multicentre Audit.","authors":"L Mackey, M Norman, D Chan","doi":"10.1111/cea.70090","DOIUrl":"https://doi.org/10.1111/cea.70090","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}